Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
AUSTIN, Texas, April 05, 2018 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present Phase 1 dose escalation data regarding the use of the Company’s pegzilarginase in patients with advanced solid tumors at the 2018 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois on Sunday, April 15.
Title: Phase I Dose Escalation Trial of Pegzilarginase in Patients with Advanced Solid Tumors
Session Title: Phase I Clinical Trials 1
Session Date and Time: Sunday, April 15, 1:00 p.m. to 5:00 p.m. CT
Session Location: McCormick Place South, Hall A, Poster Section 42
Poster Board Number: 23
Permanent Abstract Number: CT030
An electronic version of the presentation will be available for download from the Presentations & Events section of the Company’s investor relations website after the poster presentation.
About Pegzilarginase (AEB1102) in Cancer
Pegzilarginase is an enhanced human arginase that enzymatically degrades the amino acid arginine. In some cancers, tumor cells stop producing specific amino acids and must acquire them from the blood, making the tumor cells susceptible to starvation through depletion of those amino acids. Aeglea is developing pegzilarginase to exploit vulnerabilities in some cancers that lead to an increased dependency on extracellular arginine. Pegzilarginase targets these arginine dependent cancers by depleting blood arginine levels to below the normal range. Preclinical data demonstrated that the resulting arginine starvation inhibits proliferation, induces cell death, increases turnover of cell components and promotes anti-tumor immune responses. The Company’s Phase 1 data in advanced solid tumors demonstrated that pegzilarginase was well tolerated at doses that produced marked and sustained reductions in blood arginine levels below the normal range.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
[email protected]
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
[email protected]
